These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 36539738)

  • 1. Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma.
    Chen TH; Pan YY; Lee TL; Wang LW; Tai SK; Chu PY; Lo WL; Wu CH; Yang MH; Chang PM
    BMC Cancer; 2022 Dec; 22(1):1336. PubMed ID: 36539738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Takeshita N; Enokida T; Okano S; Fujisawa T; Wada A; Sato M; Tanaka H; Tanaka N; Onaga R; Hoshi Y; Sakashita S; Ishii G; Tahara M
    Oral Oncol; 2023 Dec; 147():106615. PubMed ID: 37931493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in head and neck squamous cell carcinoma (R/M-HNSCC) patients treated with first line platinum-based chemotherapy.
    Pitakpaiboonkul P; Jiarpinitnun C; Pattaranutaporn P; Ngamphaiboon N
    Cancer Med; 2024 Feb; 13(4):e7047. PubMed ID: 38457195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
    Chevalier T; Daste A; Saada-Bouzid E; Loundou A; Peyraud F; Lambert T; Le Tourneau C; Peyrade F; Dupuis C; Alfonsi M; Fayette J; Reure J; Huguet F; Fakhry N; Toullec C; Salas S
    Cancer Med; 2021 Jun; 10(12):3952-3963. PubMed ID: 34080776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors and risk-stratification model of recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regimen.
    Yang MH; Chen TH; Wang HM; Hsieh JC; Huang HC; Hsieh MC; Yen CJ; Wu SY; Hua CH; Lien MY; Chang YF; Wang HC; Chien CY; Huang TL; Lu HJ; Lin JC; Wang CC; Liu YC; Chen JP; Lu WC; Yiu CY; Lin CL; Lou PJ; Chu PY
    BMC Cancer; 2024 Oct; 24(1):1227. PubMed ID: 39369189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.
    Guo Y; Luo Y; Zhang Q; Huang X; Li Z; Shen L; Feng J; Sun Y; Yang K; Ge M; Zhu X; Wang L; Liu Y; He X; Bai C; Xue K; Zeng Y; Chang X; Chen W; Lin T
    Eur J Cancer; 2021 Oct; 156():35-45. PubMed ID: 34418665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08).
    Wang HM; Lou PJ; Yang MH; Chen TH; Lien MY; Lin JC; Chen JP; Lu WC; Lu HJ; Huang TL; Yen CJ; Wu SY; Wang HC; Hsieh MC
    Target Oncol; 2024 Jan; 19(1):51-58. PubMed ID: 38285067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence.
    Ham JC; van Meerten E; Fiets WE; Beerepoot LV; Jeurissen FJF; Slingerland M; Jonker MA; Husson O; van der Graaf WTA; van Herpen CML
    Head Neck; 2020 May; 42(5):828-838. PubMed ID: 31903657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
    Sato H; Tsukahara K; Okamoto I; Katsube Y; Shimizu A; Kondo T; Hanyu K; Fushimi C; Okada T; Miura K
    Acta Otolaryngol; 2019 Feb; 139(2):201-205. PubMed ID: 30794080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palliative chemotherapy with or without cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: Indian tertiary care retrospective analysis.
    Bahl A; Bhatia K; Choudhary P; Singhla S; Shrivastava G; Bal J; Anand AK; Chaturvedi H; Dua B
    Head Neck; 2020 May; 42(5):955-962. PubMed ID: 31916340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer.
    Cabezas-Camarero S; Cabrera-Martín MN; Merino-Menéndez S; Paz-Cabezas M; García-Barberán V; Sáiz-Pardo Sanz M; Iglesias-Moreno M; Alonso-Ovies A; Pérez-Segura P
    Oncologist; 2021 Jun; 26(6):e1018-e1035. PubMed ID: 33751752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Bossi P; Miceli R; Locati LD; Ferrari D; Vecchio S; Moretti G; Denaro N; Caponigro F; Airoldi M; Moro C; Vaccher E; Sponghini A; Caldara A; Rinaldi G; Ferrau F; Nolè F; Lo Vullo S; Tettamanzi F; Hollander L; Licitra L
    Ann Oncol; 2017 Nov; 28(11):2820-2826. PubMed ID: 28950305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors.
    Bernad IP; Trufero JM; Urquizu LC; Pazo Cid RA; de Miguel AC; Agustin MJ; Lanzuela M; Antón A
    Clin Transl Oncol; 2017 Jun; 19(6):769-776. PubMed ID: 28120324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2).
    Yokota T; Ota Y; Fujii H; Kodaira T; Shimokawa M; Nakashima T; Monden N; Homma A; Ueda S; Akimoto T
    Int J Clin Oncol; 2021 Feb; 26(2):316-325. PubMed ID: 33125596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
    Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M; Jimeno A; Adkins DR; Schneider CJ; Sacco AG; Shirai K; Bowles DW; Gibson M; Nwizu T; Gottardo R; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Cohen EEW
    JAMA Oncol; 2018 Nov; 4(11):1583-1588. PubMed ID: 29931076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incurable locoregional disease is a strong poor prognostic factor in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Nishimura A; Yokota T; Hamauchi S; Onozawa Y; Shirasu H; Kawabata T; Ogawa H; Onoe T; Iida Y; Mukaigawa T; Yasui H
    Int J Clin Oncol; 2021 Oct; 26(10):1822-1830. PubMed ID: 34152533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
    Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
    Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C
    Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma.
    Nakano K; Marshall S; Taira S; Sato Y; Tomomatsu J; Sasaki T; Shimbashi W; Fukushima H; Yonekawa H; Mitani H; Kawabata K; Takahashi S
    Oral Oncol; 2017 Oct; 73():21-26. PubMed ID: 28939072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.